Yidi Wang

Jan 13, 2025 | 2minutemedicine.com | Yidi Wang

The addition of Truqap to standard-of-care therapy improved radiographic progression-free survival in patients with metastatic prostate cancer and loss of function in PTEN protein. The addition of Truqap may improve overall survival but data collection is still ongoing.

Jan 10, 2025 | 2minutemedicine.com | Yidi Wang

The addition of Monjuvi to standard-of-care therapy reduced the risk of disease progression, relapse, or death in patients with relapsed/refractory follicular lymphomaCompared to placebo, the addition of Monjuvi did not result in a higher rate of serious adverse events. The LatestIn the randomized phase 3 in-MIND trial, patients with refractory/relapsed follicular lymphoma were randomized to standard-of-care therapy (Lenalidomide + Rituxan) and Monjuvi versus standard of care and placebo.

Oct 31, 2024 | 2minutemedicine.com | Yidi Wang

Vyloy plus standard-of-care chemotherapy extended overall survival in patients with advanced gastric cancer. The rate of grade 3 or higher adverse events was slightly higher in patients taking Vyloy compared to a placebo group. The Latest In the randomized phase 3 SPOTLIGHT and GLOW trials, researchers investigated the efficacy and safety of Vyloy in the treatment of locally advanced, unresectable, or metastatic gastric adenocarcinoma.

Oct 1, 2024 | 2minutemedicine.com | Yidi Wang

Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade 1-2 cytokine release syndrome (CRS), though severe cases (grade 3) were rare. The Latest In the EPCORE NHL-1 study, a phase 1-2, open-label, single-arm, multicohort study, 128 patients with relapsed or refractory CD20+ follicular lymphoma were treated with subcutaneous Epkinly until disease progression or unacceptable toxicity.

Sep 12, 2024 | 2minutemedicine.com | Yidi Wang

All three tested Niktimvo dosing regimens led to statistically significant overall response rates in patients who have undergone allogenic hematopoietic stem cell transplant and had recurrent or refractory cGVHD. The lowest dosing regimen of 0.3mg/kg every 2 weeks had the highest overall response rate and lowest toxicity.